Research article 2024 Reviewed

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

Meenakshi Hegde, Shoba Navai, Christopher DeRenzo, Sujith K. Joseph, Khaled Sanber, Mengfen Wu, Ahmed Z. Gad, Katherine A. Janeway, Matthew Campbell, Dolores Mullikin, Zeid Nawas, Catherine Robertson, Pretty R. Mathew, Huimin Zhang, Birju Mehta, Raksha R. Bhat, Angela Major, Ankita Shree, Claudia Gerken, Mamta Kalra, Rikhia Chakraborty, Sachin G. Thakkar, Olga Dakhova, Vita S. Salsman, Bambi Grilley, Natalia Lapteva, Adrian Gee, Gianpietro Dotti, Riyue Bao, Ahmed Hamed Salem, Tao Wang, Malcolm K. Brenner, Helen E. Heslop, Winfried S. Wels, M. John Hicks, Stephen Gottschalk, Nabil Ahmed

Nature Cancer2024-04-24Springer Science and Business Media LLC

Open original source DOI PubMed Europe PMC Explore connections

Evidence snapshot note

This reference is cited by the validated MVA · BUB1B evidence snapshot (data as of 2026-10-17) as Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.

Model in the source: People with progressive HER2-positive sarcoma, including rhabdomyosarcoma.
Where in the publication: Abstract; Table 1 and response results / Figure 4 located through indexed primary-article text.
Cited by evidence records: MVA-IMMUNE-011

The note describes how the snapshot used the source; it is not a summary of the publication's conclusions.

Identifiers and provenance

DOI: 10.1038/s43018-024-00749-6
PMID: 38658775
PMCID: PMC11588040
URL: https://www.nature.com/articles/s43018-024-00749-6
Metadata from: Crossref, Europe PMC, OpenAlex, fetched 2026-10-24
License (as declared by the source): https://www.springernature.com/gp/researchers/text-and-data-mining
Open access: Not flagged
Added: 2026-10-24 from the MVA evidence snapshot

In the library

Collections: MVA Hackathon 2026 — BUB1B
Tags: None yet
Keywords from the source: HER2, chimeric antigen receptor T cells, autologous CAR T-cell therapy, advanced sarcoma, lymphocyte depletion, fludarabine, cyclophosphamide, cytokine release syndrome, anticancer activity, tumor immune microenvironment